Open an account

Maravai LifeSciences Holdings

MRVI · NASDAQ

$7.20+$0.21 (+3.00%)TodayMarket closed ·
Prev close $6.99

About MRVI

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The company is headquartered in San Diego, California and currently employs 435 full-time employees. The company went IPO on 2020-11-20. Its segments include TriLink and Cygnus. Its TriLink segment provides nucleic acid products and related services, including messenger ribonucleic acid (mRNA), oligonucleotides, CleanCap mRNA capping technology, ModTail poly(A) tail modification technology, synthesis inputs, nucleoside triphosphates, enzymes, and mRNA manufacturing services. Its Cygnus segment provides biologics safety testing products and services, including host cell protein enzyme-linked immunosorbent assay (ELISA) kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services. Its TriLink and Cygnus segments produce materials used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products.

Employees
435
Headquarters
San Diego, California
Listed
Nov 20, 2020
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
maravai.com

MRVI key statistics

Market cap
1.87B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.60M
Volume
2.02M
Open price
$6.99
High today
$7.60
Low today
$6.99
52 Week high
$9.42
52 Week low
$2.55

Maravai LifeSciences Holdings (MRVI) at a glance

As of Oct 20, 2026, Maravai LifeSciences Holdings (MRVI) shares are priced at $7.20, giving the company a market cap of 1.87B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.99 and $7.60. The current price is 3.1% above the day's low and 5.2% below its high.

Volume so far is 2.02M shares, below the average of 2.60M shares a day.

Over the past year Maravai LifeSciences Holdings has ranged from $2.55 to $9.42, and now sits 68% of the way up that range.

Maravai LifeSciences Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.02 per share against an estimate of -$0.0441.

The average analyst price target is $7.75, 7.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $7.75
Low
$7.07
Now
$7.20
High
$8.40

MRVI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 56.0% on average.

  1. Q3 FY24: reported -$0.02 per share against an estimate of -$0.0078
  2. Q4 FY24: reported -$0.06 per share against an estimate of -$0.0408
  3. Q1 FY25: reported -$0.08 per share against an estimate of -$0.0729
  4. Q2 FY25: reported -$0.08 per share against an estimate of -$0.0723
  5. Q3 FY25: reported -$0.08 per share against an estimate of -$0.0833
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0723
  7. Q1 FY26: reported $0.01 per share against an estimate of -$0.0481
  8. Q2 FY26: reported -$0.02 per share against an estimate of -$0.0441

MRVI news

  • Press releaseBusiness Wire

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

  • Press releaseBusiness Wire

    TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseBusiness Wire

    Maravai LifeSciences Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

  • Press releaseBusiness Wire

    TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

  • Press releaseBusiness Wire

    TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

  • Press releaseBusiness Wire

    Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Similar companies

Companies in the same industry as Maravai LifeSciences Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.